文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or TNM Staging.

作者信息

Sridhar Sajeev, Abouelfetouh Zeyad, Codreanu Ion, Gupta Nakul, Zhang Shu, Efstathiou Eleni, Karolyi Daniel K, Shen Steven S, LaViolette Peter S, Miles Brian, Martin Diego R

机构信息

Department of Radiology, Houston Methodist Research Institute, Houston, Texas, USA.

Department of Radiology, Houston Methodist Research Institute, Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Moldova.

出版信息

Prostate. 2025 Apr;85(5):413-423. doi: 10.1002/pros.24843. Epub 2024 Dec 19.


DOI:10.1002/pros.24843
PMID:39702937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11848987/
Abstract

BACKGROUND: Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) in the current Prostate Imaging-Reporting and Data System version 2.1 (PI-RADS v2.1) is considered optional, with primary scoring based on T2-weighted imaging (T2WI) and diffusion weighted imaging (DWI). Our study is designed to assess the relative contribution of DCE MRI in a patient-cohort with whole mount prostate histopathology and spatially-mapped prostate adenocarcinoma (PCa) for reference. METHODS: We performed a partially-blinded retrospective review of 47 prostatectomy patients with recent multi-parametric MRI (mpMRI). Scans included T2WI, DWI with apparent diffusion coefficient (ADC) mapping, and DCE imaging. Lesion conspicuity was scored on a 10-point scale with ≥ 6 considered "positive," and image quality was assessed on a 4-point scale for each sequence. The diagnostic contribution of DCE images was evaluated on a 4-point scale. The mpMRI studies were assigned PI-RADS scores and tumor, node, metastasis (TNM) T-stage with blinded comparison to spatially-mapped whole-mount pathology. Results were compared to the prospective clinical reports, which used standardized PI-RADS templates that emphasize T2WI, DWI and ADC. RESULTS: Per lesion sensitivity for PCa was 93.5%, 82.6%, 63.0%, and 58.7% on T2WI, DCE, ADC and DWI, respectively. Mean lesion conspicuity was 8.5, 7.9, 6.2, and 6.1, on T2W, DCE, ADC and DWI, respectively. The higher values on T2WI and DCE imaging were not significantly different from each other but were both significantly different from DWI and ADC (p < 0.001). DCE scans were determined to have a marked diagnostic contribution in 83% of patients, with the most common diagnostic yield being detection of contralateral peripheral zone tumor or delineating presence/absence of extra-prostatic extension (EPE), contributing to more accurate PCa staging by PI-RADS or TNM, as compared to histopathology. CONCLUSION: We demonstrate that DCE may contribute to lesion detection and local staging as compared to T2WI plus DWI-ADC alone and that lesion conspicuity using DCE is markedly improved as compared to DWI-ADC. These findings support modification of PI-RADS v2.1 to include use of DCE acquisitions and that a TNM staging is feasible on mpMRI as compared to surgical pathology.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/ca38d7cba585/PROS-85-413-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/53c3ebaee5d5/PROS-85-413-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/ddec7cece367/PROS-85-413-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/3b8536dba6dc/PROS-85-413-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/f50b1c051c50/PROS-85-413-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/ca38d7cba585/PROS-85-413-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/53c3ebaee5d5/PROS-85-413-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/ddec7cece367/PROS-85-413-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/3b8536dba6dc/PROS-85-413-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/f50b1c051c50/PROS-85-413-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c4e/11848987/ca38d7cba585/PROS-85-413-g003.jpg

相似文献

[1]
The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or TNM Staging.

Prostate. 2025-4

[2]
Prospective evaluation of mpMRI-derived nomograms for detecting prostate cancer in PI-RADS v2.1 upgraded and non-upgraded lesions.

Front Oncol. 2025-6-4

[3]
Preoperative Diagnosis of Ipsilateral and Contralateral Breast Cancer: Role of Diffusion-weighted MRI.

Radiology. 2025-6

[4]
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.

Cochrane Database Syst Rev. 2018-1-22

[5]
MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis.

Health Technol Assess. 2024-10

[6]
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.

Radiol Imaging Cancer. 2025-1

[7]
What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Eur Urol. 2017-3-21

[8]
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.

Cochrane Database Syst Rev. 2022-5-20

[9]
Interobserver Agreement and Accuracy in Interpreting mpMRI of the Prostate: a Systematic Review.

Curr Urol Rep. 2022-1

[10]
Pelvic lymph node dissection in prostate cancer.

Eur Urol. 2009-6

引用本文的文献

[1]
An Innovative Approach with [Ga]Ga-PSMA PET/CT: The Relationship Between PRIMARY Scores and Clinical and Histopathological Findings.

Diagnostics (Basel). 2025-7-15

本文引用的文献

[1]
Biparametric versus multiparametric MRI for the detection of clinically significant prostate cancer in a diverse, multiethnic population.

Abdom Radiol (NY). 2024-7

[2]
Is PI-RADS Ready for Biparametric Prostate MRI?

AJR Am J Roentgenol. 2024-5

[3]
Biparametric Quantitative MRI for Prostate Cancer Detection.

Top Magn Reson Imaging. 2023-12-1

[4]
Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate-Unnecessary or Underutilised? A Narrative Review.

Diagnostics (Basel). 2023-11-20

[5]
[Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion].

Beijing Da Xue Xue Bao Yi Xue Ban. 2023-10-18

[6]
PI-RADS: Where Next?

Radiology. 2023-6

[7]
Could Biparametric MRI Replace Multiparametric MRI in the Management of Prostate Cancer?

Life (Basel). 2023-2-7

[8]
[Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points].

J Korean Soc Radiol. 2023-1

[9]
The Role of mpMRI in the Assessment of Prostate Cancer Recurrence Using the PI-RR System: Diagnostic Accuracy and Interobserver Agreement in Readers with Different Expertise.

Diagnostics (Basel). 2023-1-20

[10]
Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy.

Cancer Imaging. 2022-12-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索